Use of cystic fibrosis inhaled medication before and after elexacaf tor/tezacaf tor/ivacaf tor initiation

被引：7

作者：

Manika, Katerina ^{[1
]}

Diamantea, Filia ^{[2
]}

Tsakona, Anna ^{[1
]}

Kakolyris, Alexandros ^{[2
]}

Sopiadou, Athina ^{[3
]}

Kotoulas, Serafeim-Chrysovalantis ^{[1
]}

Sionidou, Maria ^{[1
]}

Kirvasili, Sirmo-Stiliani ^{[3
]}

Hadji-Mitrova, Marija ^{[1
]}

Papadaki, Eleni ^{[1
]}

Chrysochoou, Elisavet-Anna ^{[3
]}

Hatziagorou, Elpis ^{[3
]}

机构：

[1] Aristotle Univ Thessaloniki, G Papanikolaou Hosp, Pulm Dept, Adult CF Unit, Thessaloniki 57010, Greece

[2] Sismanoglio Hosp, Adult CF Unit, Sismanogliou 1, Athens 15126, Greece

[3] Aristotle Univ Thessaloniki, Hippokrat Hosp, Paediat Dept 3, Cyst Fibrosis Unit, Kostantinoupoleos 49, Thessaloniki 54642, Greece

来源：

JOURNAL OF CYSTIC FIBROSIS | 2024年 / 23卷 / 01期

关键词：

Cystic fibrosis; CFTR modulators; Inhaled medications; Use of treatment; Medication Possession Ratio; Multi-center study; GUIDELINES; PEOPLE;

D O I：

10.1016/j.jcf.2023.05.001

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Elexacator/tezacaftor/ivacaftor (ETI) has improved cystic fibrosis (CF) outcomes. A reduction in use of maintenance medication after its initiation has been reported. Seventy-one adult people with CF (PwCF) who are followed in three CF centers and completed one year of treatment with ETI were included in this study. Their use of inhaled dornase- alpha, colistin, tobramycin, aztreonam and levofloxacin during this period was compared with the corresponding use during one year without ETI, using the Medication Possession Ratio (MPR). MPR was significantly decreased after ETI initiation for dornase- alpha (67 +/- 35% vs 48 +/- 40%, p < 0.001) and for all four inhaled antibiotics together (62 +/- 33% vs 41 +/- 37%, p < 0.001). The findings of this multi-center, retrospective, study suggest that the initiation of ETI significantly leads to decrease in use of standard inhaled medication in PwCF. The significance of this finding in the course of the disease is yet to be investigated by larger prospective clinical trials. (c) 2023 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

引用

页码：29 / 31

页数：3

共 25 条

[21] Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaf tor/ivacaf tor compared to males
Aalbers, B. L.
Hofland, R. W.
Bronsveld, I.
Groot, K. M. de Winter-de
Arets, H. G. M.
Kiviet, A. C. de
Ven, M. M. M. van Oirschot-van de
Kruijswijk, M. A.
Schotman, S.
Michel, S.
Ent, C. K. van der
Heijerman, H. G. M.
JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (01) : E7 - E11
[22] VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaf tor/ivacaf tor trial
Wilson, John
You, Xiaojun
Ellis, Matt
Urquhart, Don S.
Jha, Lokesh
Duncan, Margaret
Tian, Simon
Harris, Ryan A.
Kotsimbos, Tom
Keating, Dominic
JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (03) : 499 - 505
[23] Medication use in people with cystic fibrosis before and after modulator therapy
Lord, Louise
Hew, Mark
Leung, Miriam T. Y.
Morton, Jedidiah I.
Ilomaki, Jenni
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2023, 83
[24] Pulmonary deposition of inhaled tobramycin prior to and after respiratory therapy and use of inhaled albuterol in cystic fibrosis patients colonized with Pseudomonas aeruginosa
Grotta, Milena Baptistella
de Sa Camargo Etchebere, Elba Cristina
Ribeiro, Antonio Fernando
Romanato, Juliana
Goncalves de Oliveira Ribeiro, Maria Angela
Ribeiro, Jose Dirceu
JORNAL BRASILEIRO DE PNEUMOLOGIA, 2009, 35 (01) : 35 - 43
[25] Emergence of vancomycin-resistant Enterococcus faecium after use of inhaled vancomycin in a cystic fibrosis patient chronically infected with methicillin-resistant Staphylococcus aureus
Ferreira da Silva Filho, Luiz Vicente Ribeiro
Adde, Fabiola Villac
Fongaro, Giuliana de Freitas
de Menezes, Luciana Correia
Rossi Junior, Alfio
Rodrigues, Joaquim Carlos
EINSTEIN-SAO PAULO, 2008, 6 (03): : 356 - 358

← 1 2 3 →